Results 111 to 120 of about 5,331,742 (248)

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

International Journal of Cancer, EarlyView.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari, Pablo Hoffmann, Laura Reichl, Maximilian Schmutz, Nina Fischer, Thi Tuong Vi Dang, Fulvia Ferrazzi, Pascal Johann, Michaela Kuhlen, Constantin Lapa, Rainer Claus   +10 more
wiley   +1 more source

New‐Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank

International Journal of Cancer, EarlyView.
ABSTRACT The prevalence of type 2 diabetes mellitus (T2DM) is rising rapidly in China and is linked to increased cancer risk, but causality remains unclear due to biases. We examined the causal effect of T2DM on cancer risk using bias‐minimizing methods.
Mengying Wang, Owen Tipping, Bowen Liu, Derrick A. Bennett, Baiyong Shen, Siyi Zou, Shulin Zhao, Richard M. Martin, Matthew Sperrin, Andrew G. Renehan   +9 more
wiley   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source

Epidemiology of esophageal and hypopharyngeal squamous cell carcinoma

, 2011
The incidence of esophageal squamous cell carcinoma (SCC) exceeds that of esophageal adenocarcinoma (AC) in all developing countries and in most developed countries, including Italy. By contrast, the incidence of AC has recently approached that of SCC in
DE MANZONI, Giovanni, VERLATO, Giuseppe
core   +1 more source

A Pan‐Cancer Single‐Cell Atlas of Bone Metastases Reveals Convergent Malignant Programs and Coordinated Immune Dysfunction

iMetaMed, EarlyView.
A pan‐cancer atlas deciphers tumor‐induced reprogramming in bone metastases. Malignant evolution toward MYC/proliferation is a hallmark of bone metastases. Niche‐mediated immune dysfunction is characterized by immature pDCs, impaired antigen presentation and phagocytosis in TAMs, and exhausted T cells.
Yitong Pan, Zhou Yang, Junyuan Deng, Feng Liu, Guang Lei   +4 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives

JSFA reports, EarlyView.
Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz, Muhammad Tauseef Sultan, Muhammad Israr, Waqas Ahmad Khan, Fahad Tanveer, Muzzamal Hussain, Muhammad Imran, Ahmed Mujtaba, Anjuman Gul Memon, Muhammad Atif, Entessar Al Jbawi   +10 more
wiley   +1 more source

Andrographolide Modulates Fibrogenic and Oxidative Stress Responses in Human Lung Fibroblasts

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Pulmonary fibrosis is a progressive lung disorder characterized by fibroblast activation and excessive extracellular matrix deposition. Andrographolide (ANDRO) has been reported to attenuate pulmonary fibrosis, but the underlying molecular mechanisms remain incompletely understood.
Yu‐Hsin Tseng, Yen‐Hsien Wu, Yi‐Ching Liu, I‐Chen Chen, Chung‐Yu Yeh, Shang‐En Huang, Ren‐Long Jan, Jwu‐Lai Yeh, Jong‐Hau Hsu   +8 more
wiley   +1 more source

Proliferative and survival pathways in oesophageal cancer [PDF]

, 2011
Includes abstract.Includes bibliographical references.Oesophageal squamous cell carcinoma (OSCC) is the 8th most common cancer worldwide with high incidence in areas that include China, Iran and South Africa. The current treatment available for OSCC does
Esau, Luke Emmanuel
core   +1 more source